United-Guardian (UG) 10-K 26 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 01, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	UNITED GUARDIAN INC
Document Type	10-K
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		4,596,439
Entity Public Float			$74,690,668
Amendment Flag	FALSE
Entity Central Index Key	101295
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Statements_of_Income

Statements of Income (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Net sales	$13,449,679	$15,416,893
Costs and expenses:
Cost of sales	5,317,707	5,610,813
Operating expenses	2,640,997	2,504,526
Total costs and expenses	7,958,704	8,115,339
Income from operations	5,490,975	7,301,554
Other income:
Investment income	239,592	259,747
Income from damage settlement	24,403	1,070,561
Total other income	263,995	1,330,308
Income from operations before income taxes	5,754,970	8,631,862
Provision for income taxes	1,704,554	2,728,553
Net income	$4,050,416	$5,903,309
Earnings per common share (basic and diluted) (in Dollars per share)	$0.88	$1.28
Weighted average shares (basic and diluted) (in Shares)	4,596,439	4,596,439

Statements_of_Comprehensive_In

Statements of Comprehensive Income (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Net income	$4,050,416	$5,903,309
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	191,533	-71,711
Income tax (expense) benefit	-63,787	24,855
Other comprehensive income (loss), net of tax	127,746	-46,856
Comprehensive income	$4,178,162	$5,856,453

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$2,023,383	$1,634,262
Marketable securities	9,389,501	8,863,205
Accounts receivable, net of allowance for doubtful accounts of $30,000 in 2014 and $18,000 in 2013	1,593,260	1,790,747
Receivable in connection with damage settlement		48,805
Inventories (net)	1,237,154	1,610,747
Prepaid expenses and other current assets	165,691	130,001
Prepaid income taxes	30,643
Deferred income taxes	223,439	229,451
Total current assets	14,663,071	14,307,218
Property, plant, and equipment:
Land	69,000	69,000
Factory equipment and fixtures	4,138,875	4,090,968
Building and improvements	2,773,002	2,766,319
Waste disposal system		133,532
Total property, plant and equipment	6,980,877	7,059,819
Less accumulated depreciation	5,772,974	5,725,318
Net property, plant, and equipment	1,207,903	1,334,501
Other assets:	68,042	9,147
Total assets	15,939,016	15,650,866
Current liabilities:
Accounts payable	141,111	385,699
Accrued expenses	833,859	728,015
Income taxes payable		131,638
Total current liabilities	974,970	1,245,352
Deferred income taxes	227,108	169,587
Commitments and contingencies
Common stock, $.10 par value; 10,000,000 shares authorized; 4,596,439 shares issued and outstanding at December 31, 2014 and 2013, respectively	459,644	459,644
Accumulated other comprehensive income	259,869	132,123
Retained earnings	14,017,425	13,644,160
Total stockholders’ equity	14,736,938	14,235,927
Total liabilities and stockholders’ equity	$15,939,016	$15,650,866

Balance_Sheets_Parentheticals

Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accounts receivable, allowance (in Dollars)	$30,000	$18,000
Common stock, par value (in Dollars per share)	$0.10	$0.10
Common stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	4,596,439	4,596,439
Common stock, shares outstanding	4,596,439	4,596,439

Statement_Of_Stockholders_Equi

Statement Of Stockholders' Equity (USD $)	Common Stock [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2012	$459,644	$178,979	$12,199,395	$12,838,018
Balance (Shares) (in Shares) at Dec. 31, 2012	4,596,439
Change in unrealized gains on marketable securities, net of deferred income tax		-46,856		-46,856
Net income			5,903,309	5,903,309
Dividends declared			-4,458,544	-4,458,544
Balance at Dec. 31, 2013	459,644	132,123	13,644,160	14,235,927
Balance (Shares) (in Shares) at Dec. 31, 2013	4,596,439
Change in unrealized gains on marketable securities, net of deferred income tax		127,746		127,746
Net income			4,050,416	4,050,416
Dividends declared			-3,677,151	-3,677,151
Balance at Dec. 31, 2014	$459,644	$259,869	$14,017,425	$14,736,938
Balance (Shares) (in Shares) at Dec. 31, 2014	4,596,439

Statement_Of_Stockholders_Equi1

Statement Of Stockholders' Equity (Parentheticals) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Change in unrealized gains on marketable securities, deferred income tax benefit	($63,787)	$24,855

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income	$4,050,416	$5,903,309
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	181,188	189,729
Realized loss (gain) on sales of marketable securities	25,127	-18,675
Increase (decrease) in allowance for bad debts	12,325	-11,089
Deferred income taxes	-254	-12,161
Increase (decrease) in cash resulting from changes in operating assets and liabilities:
Accounts receivable	185,162	-762,031
Receivable from damage settlement	48,805	469,245
Inventories	373,593	-367,997
Prepaid expenses and other current and non-current assets	-94,585	-6,690
Prepaid income taxes	-30,643	3,602
Accounts payable	-244,588	234,314
Accrued expenses and taxes payable	-25,794	183,530
Net cash provided by operating activities	4,480,752	5,805,086
Cash flows from investing activities:
Acquisitions of plant and equipment	-54,590	-288,367
Purchases of marketable securities	-3,437,478	-5,311,313
Proceeds from sales of marketable securities	3,077,588	4,139,018
Net cash used in investing activities	-414,480	-1,460,662
Cash flows from financing activities:
Dividends paid	-3,677,151	-4,458,544
Net cash used in financing activities	-3,677,151	-4,458,544
Net increase (decrease) in cash and cash equivalents	389,121	-114,120
Cash and cash equivalents, beginning of year	1,634,262	1,748,382
Cash and cash equivalents, end of year	$2,023,383	$1,634,262

Note_A_Nature_of_Business_and_

Note A - Nature of Business and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	NOTE A - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Nature of Business
	United-Guardian, Inc. (the "Company") is a Delaware corporation that, through its Guardian Laboratories Division, manufactures and markets cosmetic ingredients, personal care products, pharmaceuticals, medical lubricants, health care products, and specialty industrial products. It also conducts research and product development, primarily related to the development of new and unique cosmetic and personal care products. The Company’s research and development department also modifies, refines, and expands the uses for existing products, with the goal of further developing the market for the Company's products. Two major product lines, LUBRAJEL™ and RENACIDIN® IRRIGATION (“RENACIDIN”) together accounted for 94.6% and 94.4% of revenue for the years ended December 31, 2014 and December 31, 2013, respectively. LUBRAJEL accounted for 85.9% and 91.4% of revenue for the years ended December 31, 2014 and December 31, 2013, respectively, and RENACIDIN accounted for 8.8% and 2.9% of revenue for the years ended December 31, 2014 and December 31, 2013, respectively.
	Accounts Receivable and Reserves
	The carrying amount of accounts receivable is reduced by a valuation allowance that reflects our best estimate of the amounts that will not be collected. The reserve for accounts receivable comprises the allowance for doubtful accounts and sales returns. In addition to reviewing delinquent accounts receivable, we consider many factors in estimating our reserve, including historical data, experience, customer types and credit worthiness, and economic trends. From time to time, we adjust our assumptions for anticipated changes in any of these or other factors expected to affect collectability.
	Revenue Recognition
	The Company recognizes revenue when products are shipped, title and risk of loss pass to customers, persuasive evidence of a sales arrangement exists, and collections are reasonably assured.  All products are shipped Free On Board (“FOB”) Hauppauge, New York, the location of the Company’s plant. Both title and risk of loss are deemed by both the Company and its customers to have passed to the customers at the time the goods leave the Company’s plant. Shipments are only made after confirmation that a valid purchase order has been received and that the future collection of the sale amount is reasonably assured. All sales of the Company’s products are deemed final, and there is no obligation on the part of the Company to repurchase or allow the return of the goods unless they are defective. The Company does not make sales on consignment, and the collection of the proceeds of the sale is not contingent upon the customer being able to sell the goods to a third party.
	Any allowance for returns is taken as a reduction of sales within the same period the revenue is recognized. Such allowances are based on historical experience. The Company has not experienced significant fluctuations between estimated allowances and actual activity.
	From time to time during 2014 the Company offered discounts and/or rebates to some of its customers in order to retain or increase sales to those customers. In 2014 those sales discounts totaled $119,965, compared with $11,000 in 2013. Of the $119,965 in sales discounts in 2014, $23,965 had been paid, and $96,000 accrued, as of December 31, 2014. The $96,000 of accrued sales discounts consisted of rebates given to one of the Company’s largest customers in order to retain and increase its business with that customer.
	Cash and Cash Equivalents
	For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at inception. The Company deposits cash and cash equivalents with high credit quality financial institutions and believes that any amounts in excess of insurance limitations to be at minimal risk. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation up to a maximum of $250,000.
	Dividends
	On May 14, 2014, the Company’s Board of Directors declared a semi-annual cash dividend of $0.48 per share, which was paid on June 13, 2014 to all stockholders of record as of May 30, 2014. On November 20, 2014, the Company’s Board of Directors declared a semi-annual cash dividend of $0.32 per share, which was paid on December 22, 2014 to all stockholders of record as of December 8, 2014. Total dividends declared and paid in 2014 were $3,677,151.
	On May 15, 2013, the Company’s Board of Directors declared a semi-annual cash dividend of $0.47 per share, which was paid on June 14, 2013 to all stockholders of record as of May 30, 2013. On November 22, 2013, the Company’s Board of Directors declared a semi-annual cash dividend of $0.50 per share, which was paid on December 20, 2013 to all stockholders of record as of December 6, 2013. Total dividends declared and paid in 2013 were $4,458,544.
	Supplemental Disclosures of Non-cash Investing and Financing Activities
	Cash payments for income taxes were $1,867,089 and $2,605,474 for the years ended December 31, 2014 and 2013, respectively.
	Marketable Securities
	Marketable securities include investments in equity and fixed income mutual funds, and government securities, all of which have a high degree of liquidity, are classified as "Available for Sale" securities, and are reported at their fair values. Unrealized gains and losses on "Available for Sale" securities are reported as accumulated other comprehensive income (loss) in stockholders' equity, net of the related tax effects. Investment income is recognized when earned. Realized gains and losses on sales of investments and declines in value judged to be other than temporary, if any, are reported in other income with cost being determined on a specific identification basis. Fair values are based on quoted market prices. The Company evaluates its investments periodically for possible impairment and reviews factors such as the length of time and extent to which fair value has been below cost basis and the Company’s ability and intent to hold the investment for a period of time which may be sufficient for anticipated recovery in market value.
	Inventories
	Inventories are valued at the lower of cost or current market value. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Inventory costs include material, labor and factory overhead.
	Property, Plant and Equipment
	Property, plant and equipment are carried at cost, less accumulated depreciation. Major replacements and betterments are capitalized, while routine maintenance and repairs are expensed as incurred. Assets are depreciated under both accelerated and straight-line methods. Depreciation charged to income as a result of using accelerated methods was not materially different than that which would result from using the straight-line method for all periods presented. Certain factory equipment and fixtures are constructed by the Company using purchased materials and in-house labor. Such assets are capitalized and depreciated on a basis consistent with the Company's purchased fixed assets.
	Estimated useful lives are as follows:
	Factory equipment and fixtures (years)	5	-	7
	Building  (years)		40
	Building improvements		Lesser of useful
			life or 20 years
	Waste disposal system  (years)		7
	Impairment of Long-Lived Assets
	Long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.  No impairments were necessary at December 31, 2014 and 2013.
	Other Assets
	Other assets at December 31, 2014 consisted of $60,042 expended in connection with the development of a new dosage form and manufacturing process for RENACIDIN, and $8,000 in costs incurred in re-registering the Company’s LUBRAJEL trademark. The Company will determine the appropriate amortization rate for these assets at such time as they are put into service.
	Fair Value of Financial Instruments
	Management of the Company believes that the fair value of financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximates their carrying value due to their short payment terms and liquid nature.
	Concentration of Credit Risk
	Accounts receivable potentially exposes the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether any credit should be given at all.  It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable.  As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its accounts receivable credit risk has been reduced.
	For the year ended December 31, 2014, two of the Company’s distributors and marketing partners accounted for 64.7% of the Company’s revenues during the year, and 56.3% of its outstanding accounts receivable at year end. For the year ended December 31, 2013, two of the Company’s distributors and marketing partners, one the same as in 2014, and the other different, accounted for a total of 69% of the Company’s revenues during the year, and 72% of its outstanding accounts receivable at year end.
	Vendor Concentration
	The principal raw materials used by the Company consist of common industrial organic and inorganic chemicals. Most of these materials are available in ample supply from numerous sources. The Company has five major raw material vendors that collectively accounted for approximately 84% and 67% of the raw material purchases by the Company in 2014 and 2013, respectively.
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to the temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
	Uncertain tax positions are accounted for utilizing a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As of December 31, 2014 and 2013, the Company did not have any unrecognized income tax benefits.  It is the Company’s policy to recognize interest and penalties related to taxes as interest expense as incurred.  During the years ended December 31, 2014 and 2013 the Company did not record any interest or penalties. The Company’s tax returns are subject to examination by the United States Internal Revenue Service and by the State of New York for years 2010 through 2013. In March 2014 the New York State Department of Taxation and Finance (“DTF”) commenced a routine examination of the Company’s income tax returns for years 2010 through 2012. The DTF has completed its examination and has accepted the tax returns as filed.
	Research and Development
	The Company's research and development expenses, included in operating expenses, are recorded in the year incurred. Research and development expenses were approximately $730,000 and $717,000 for the years ended December 31, 2014 and 2013, respectively.
	Shipping and Handling Costs
	Shipping and handling costs are classified in operating expenses in the accompanying statements of income. Shipping and handling costs were approximately $86,000 and $45,000 for the years ended December 31, 2014 and 2013, respectively.
	Advertising Costs
	Advertising costs are expensed as incurred. During 2014 and 2013 the Company incurred $20,000 and $16,000, respectively, in advertising costs.
	Stock-Based Compensation
	In 2004, the Company approved a stock option plan ("2004 Stock Option Plan") authorizing the granting of stock options to Company employees and Directors. No options were ever issued under this plan, and it expired in March 2014.
	Earnings Per Share Information
	Basic earnings per share are computed by dividing net income by the weighted average number of common shares outstanding during the year. Diluted earnings per share include the dilutive effect of outstanding stock options.
	Use of Estimates
	In preparing financial statements in conformity with U.S. generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for bad debts, possible impairment of marketable securities, reserve for inventory obsolescence, and the allocation of overhead.
	New Accounting Standards
	In December of 2013, FASB issued ASU 2013-11, “Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” This amendment requires that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with exceptions.  This amendment only applies to entities that have an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. This update became effective for interim and annual reporting periods beginning after December 15, 2013. The update does not have a material impact on the Company’s results of operation.
	In May 2014, FASB issued ASU 2014-09, “Revenue from Contracts with Customers.” This standard applies to any entity that uses the guidance of GAAP for entering into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. It requires that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration the entity expects to receive for the exchange of goods or services. This amendment is effective for interim and annual reporting periods beginning after December 15, 2016. The Company is still evaluating the potential impact on the Company’s results of operations.
	In June 2014, FASB issued ASU 2014-11, “Transfers and Servicing: Repurchase-to-Maturity Transactions, Repurchase Financings, and Disclosures.” This standard aligns the accounting for repurchases-to-maturity transactions and repurchase agreements executed as a repurchase financing with accounting for other typical repurchase agreements. These types of transactions will now be accounted for as secured borrowings. It eliminates sales accounting for repurchase-to-maturity and supersedes guidance for accounting transactions involving transfers of financial assets with contemporaneous repurchase financing agreements that leads to off-balance accounting. This update becomes effective for interim and annual reporting periods beginning after December 15, 2014 and is not expected to have a material impact on the Company’s results of operations.
	In August 2014, FASB issued ASU 2014-15, “Presentation of Financial Statements-Going Concern.  Disclosure of Uncertainties about Entity’s Ability to Continue as a Going Concern.” Currently, GAAP lacks guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern. This amendment now provides guidance by providing a definition of substantial doubt, requires evaluation by management every reporting period for going concern issues, provides principles for considering any mitigating effects implemented by management, and the disclosures required for the assessment period of one year after issuance of the financial statements. This update becomes effective for interim and annual reporting periods beginning after December 15, 2016 with early application being permitted. The update will be adopted for reporting periods starting January 2015, and is not expected to have a material impact on the Company’s results of operations.

Note_B_Marketable_Securities

Note B - Marketable Securities	12 Months Ended
	Dec. 31, 2014
Investments, Debt and Equity Securities [Abstract]
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	NOTE B - MARKETABLE SECURITIES
	The fair values of the Company’s marketable securities are determined in accordance with GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by GAAP, which prioritizes the inputs used in measuring fair value as follows:
		•	Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
		•	Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
		•	Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.
	The following available-for-sale securities, which comprise all of the Company's marketable securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs using quoted prices (unadjusted) for identical assets in active markets:
	31-Dec-14		Cost		Fair Value		Unrealized
							Gain/(Loss)
	Available for sale:
	Fixed income mutual funds		$	8,373,674	$	8,575,285	$	201,611
	Equity and other mutual funds			622,086		814,216		192,130
			$	8,995,760	$	9,389,501	$	393,741
	31-Dec-13
	Available for sale:
	Corporate bonds (maturing within 1 year)		$	203,920	$	200,053	$	(3,867	)
	Fixed income mutual funds			7,325,930		7,425,687		99,757
	Equity and other mutual funds			1,131,147		1,237,465		106,318
			$	8,660,997	$	8,863,205	$	202,208
	Proceeds from the sale and redemption of marketable securities amounted to $3,077,588 and $4,139,018 for the years ended December 31, 2014 and 2013, respectively. Losses of $25,127 and gains of $18,675 were realized for the years ended December 31, 2014 and 2013, respectively.
	Investment income consisted principally of unrealized and realized gains and losses, interest income from bonds and money market funds, and dividend income from bond funds and mutual funds.

Note_C_Inventories

Note C - Inventories	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	NOTE C – INVENTORIES
	Inventories consist of the following:
		December 31,
		2014		2013
	Raw materials and work-in-process	$	395,092	$	488,757
	Finished products		842,062		1,121,990
		$	1,237,154	$	1,610,747
	Finished product inventories at December 31, 2014 and 2013 are stated net of a reserve of $20,000 for slow moving and obsolete items.

Note_D_Income_Taxes

Note D - Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE D – INCOME TAXES
	The provision for income taxes consists of the following:
		Years ended December 31,
		2014			2013
	Current
	Federal	$	1,714,387		$	2,721,068
	State		(9,579	)		19,646
			1,704,808			2,740,714
	Deferred
	Federal		(4,003	)		(11,810	)
	State		3,749			(351	)
			(254	)		(12,161	)
	Total provision for income taxes	$	1,704,554		$	2,728,553
	The following is a reconciliation of the Company’s effective income tax rate to the Federal statutory rate (dollar amounts have been rounded to the nearest thousand):
		Years ended December 31,
		2014						2013
		($)			Tax rate			($)			Tax rate
	Income taxes at statutory federal income tax rate of 34%	$	1,957,000			34	%	$	2,935,000			34	%
	State income taxes, net of Federal benefit		(4,000	)		(0.1	)		13,000			0.2
	Domestic Production Activities tax benefit		(168,000	)		(2.9	)		(180,000	)		(2.1	)
	Nondeductible expenses		1,000			---			1,000			---
	Prior year over-accrual		(56,000	)		(1.0	)		(19,000	)		(0.2	)
	R&D credits		(25,000	)		(0.4	)		(20,000	)		(0.2	)
	Other, misc.		---			---			(1,000	)		---
	Actual income tax expense	$	1,705,000			29.6	%	$	2,729,000			31.7	%
	During 2014 and 2013, the Company realized the tax benefits of the Domestic Production Activities deduction, which amounted to approximately 9% of net income from domestic production activities in each year.
	The tax effects of temporary differences which comprise the deferred tax assets and liabilities are as follows:
		Years ended December 31,
		2014			2013
	Deferred tax assets
	Current
	Accounts receivable	$	10,164		$	6,089
	Inventories		14,037			16,862
	Accrued expenses		199,238			206,500
			223,439			229,451
	Deferred tax liabilities
	Non-current
	Depreciation		(93,236	)		(99,502	)
	Unrealized gain on marketable securities		(133,872	)		(70,085	)
			(227,108	)		(169,587	)
	Net deferred tax (liability) asset	$	(3,669	)	$	59,864

Note_E_Benefit_Plans

Note E - Benefit Plans	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE E - BENEFIT PLANS
	Defined Contribution Plan
	The Company sponsors a 401(k) defined contribution plan ("DC Plan") that provides for a dollar-for-dollar employer matching contribution of the first 4% of each employee's pay. Employees become fully vested in employer matching contributions after one year of employment. Company 401(k) matching contributions were approximately $103,000 and $101,000 for each of the years ended December 31, 2014 and 2013.  In 2014 and 2013 employees were able to defer up to $17,500 for each year respectively (plus $5,500 for employees over the age of 50) of their yearly pay as a pre-tax investment in the 401(k)plan, in accordance with limits set by the IRS. (Those limits have been increased to $18,000 (plus an additional $6,000 for employees over the age of 50) for the year 2015).
	The Company also makes discretionary contributions to each employee's account based on a "pay-to-pay" safe-harbor formula that qualifies the 401(k) plan under current IRS regulations. In December 2014 and 2013 the Company’s Board of Directors authorized discretionary contributions in the amount of $175,000 per year, to be allocated among all eligible employees, for the 2014 and 2013 plan years. The 2014 contribution was paid in 2014, and the 2013 contribution was paid in 2013. Employees become vested in the discretionary contributions as follows: 20% after two years of employment, and 20% for each year of employment thereafter until the employee becomes fully vested after six years of employment.
	Stock Option Plans
	In March 2004 the Board of Directors of the Company approved the adoption of the 2004 Stock Option Plan, which authorized the granting of stock options to both employees and Directors. The plan was ratified by the shareholders on May 19, 2004. No options were ever granted under the plan, and it expired in March 2014.

Note_F_Geographic_and_Other_In

Note F - Geographic and Other Information	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	NOTE  F -  GEOGRAPHIC and OTHER INFORMATION
	Through its Guardian Laboratories division the Company manufactures and markets cosmetic ingredients, personal care products, pharmaceuticals, medical lubricants, health care products, and specialty industrial products.  It also conducts research and development, primarily related to the development of new and unique cosmetic and personal care products. The Company’s R&D department not only develops new products but also modifies and refines existing products, with the goal of expanding the potential markets for the Company’s products. Many of the cosmetic ingredient products manufactured by Guardian, particularly its LUBRAJEL line of water-based moisturizing and lubricating gels, are currently used by many of the major multinational personal care products companies.
	The Company operates in one business segment. The Company’s products are separated into four distinct product categories: personal care products (including cosmetic ingredients), pharmaceuticals, medical products, and industrial products. Each product category is marketed differently. The cosmetic ingredient/personal care products are marketed through a global network of marketing partners and distributors.  These marketing partners purchase product outright from the Company and market and re-sell those products to the end users.  The Company does not make any sales on consignment.
	No prior regulatory approval was needed by the Company to sell any products other than its pharmaceutical products.  The end users of its products may or may not need regulatory approvals, depending on the intended claims and uses of those products.
	The pharmaceutical products are two urological products that are sold to end users primarily through distribution agreements with the major drug wholesalers. For these products, the Company does the marketing, and the drug wholesalers supply the product to the end users, such as hospitals and pharmacies. These products are drug products that required the Company to obtain regulatory approval before marketing.
	The medical products are not pharmaceutical products. They consist primarily of medical lubricants, which are marketed by the Company directly to manufacturers that incorporate them into urologic catheters and other medical devices and products that they sell. These products are distinguished from the pharmaceutical products in that, unlike the pharmaceutical products, the Company is not required to obtain regulatory approval prior to marketing these products. Approvals are the responsibility of the company that markets the medical device.  However, the Company is responsible for manufacturing these products in accordance with current Good Manufacturing Practices for medical devices.
	The industrial products are also marketed by the Company directly to manufacturers, and generally do not require that the Company obtain regulatory approval. However, the manufacturers of the finished products may have to obtain such regulatory approvals before marketing these products.
	The geographic information set forth in table "(b)" below is partially based on sales information provided to the Company by Customer A (shown in table "(c)" below), which exclusively markets the Company's cosmetic ingredients in Canada and China, and also sells some of the Company's products into France on a non-exclusive basis along with Customer B.
	(a)	Net Sales
			Years ended December 31,
			2014			2013
	Personal Care		$	9,421,041		$	11,459,482
	Medical			2,494,205			3,028,659
	Pharmaceutical			1,686,563			916,927
	Industrial and other			169,486			164,014
				13,771,295			15,569,082
	Less: Discounts and allowances			(321,616	)		(152,189	)
			$	13,449,679		$	15,416,893
	(b)	Geographic Information
			Years ended December 31,
			2014						2013
			Revenues			Long-Lived			Revenues		Long-Lived
						Assets					Assets
	United States		$	4,723,779		$	1,207,903		$	4,580,429	$	1,334,501
	China			3,500,955			---			3,519,450		---
	Canada			2,436,596			---			3,390,619		---
	United Kingdom			703,142			---			846,730		---
	India			615,890						431,015
	France			582,478			---			856,285		---
	Other countries			886,839			---			1,792,365		---
			$	13,449,679		$	1,207,903		$	15,416,893	$	1,334,501
	(c)	Sales to Major Customers
			Years ended December 31,
			2014			2013
	Customer A		$	7,929,208		$	9,712,382
	Customer B			582,478			856,285
	Customer C			615,890			431,015
	All other customers			4,322,103			4,417,211
			$	13,449,679		$	15,416,893
	Customer A had one customer that comprised 32% of Customer A’s sales of the Company’s products in 2014, and 36% of its sales in 2013.

Note_G_Comprehensive_Income

Note G - Comprehensive Income	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Comprehensive Income (Loss) Note [Text Block]	NOTE G – COMPREHENSIVE INCOME
	Accumulated other comprehensive income comprises unrealized gains and losses on marketable securities net of the related tax effect.
	Changes in Accumulated Other	31-Dec-14			31-Dec-13
	Comprehensive Income
	Beginning balance - net of tax	$	132,123		$	178,979
	Unrealized gain/(loss) on marketable securities before reclassifications - net of tax		152,873			(65,531	)
	Realized (loss)/gain on sale of securities reclassified from accumulated other comprehensive income		(25,127	)		18,675
	Ending balance - net of tax	$	259,869		$	132,123

Note_H_Income_From_Damage_Sett

Note H - Income From Damage Settlement	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Interest and Other Income [Text Block]	NOTE H - INCOME FROM DAMAGE SETTLEMENT
	In May 2012 the supplier of one of the Company’s pharmaceutical products, RENACIDIN, curtailed production due to manufacturing issues. In January 2013 the Company and its supplier entered into a settlement agreement whereby the supplier agreed to pay the Company $518,050 for the profit the Company lost during 2012 as result of the curtailment, plus $97,610 a month beginning January 1, 2013 for each month that the curtailment continued; $48,805 for each of the first two months after shipments resumed; and a final payment of $24,403 for the third month after shipments resumed. Because deliveries resumed at the end of October 2013, the supplier’s obligation to pay $97,610 per month ceased as of that date.  By the end of the first quarter of 2014 all damage payments had been made. As a result, the Company received only $24,403 in damage settlement payments for the year ended December 31, 2014, as compared with $1,070,561 for the year ended December 31, 2013.

Note_I_Accrued_Expenses

Note I - Accrued Expenses	12 Months Ended
	Dec. 31, 2014
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Other Liabilities Disclosure [Text Block]	NOTE I - ACCRUED EXPENSES
	Accrued expenses at December 31, 2014 and 2013 consist of:
		2014		2013
	Bonuses	$	225,000	$	250,000
	Distribution fees		203,483		196,558
	Payroll and related expenses		127,585		104,394
	Annual report expenses		61,000		66,000
	Audit fee		82,000		73,269
	Sales rebates		96,000		---
	Other		38,791		37,794
		$	833,859	$	728,015

Note_J_Related_Party_Transacti

Note J - Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE J - RELATED PARTY TRANSACTIONS
	During each of the years ended December 31, 2014 and 2013 the Company paid to Bonamassa, Maietta, and Cartelli, LLP, $17,000, and $14,000, respectively, for accounting and tax services. Lawrence Maietta, a partner in Bonamassa, Maietta, and Cartelli, LLP, is a director of the Company.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Loans and Leases Receivable, Allowance for Loan Losses Policy [Policy Text Block]	Accounts Receivable and Reserves
	The carrying amount of accounts receivable is reduced by a valuation allowance that reflects our best estimate of the amounts that will not be collected. The reserve for accounts receivable comprises the allowance for doubtful accounts and sales returns. In addition to reviewing delinquent accounts receivable, we consider many factors in estimating our reserve, including historical data, experience, customer types and credit worthiness, and economic trends. From time to time, we adjust our assumptions for anticipated changes in any of these or other factors expected to affect collectability.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
	The Company recognizes revenue when products are shipped, title and risk of loss pass to customers, persuasive evidence of a sales arrangement exists, and collections are reasonably assured.  All products are shipped Free On Board (“FOB”) Hauppauge, New York, the location of the Company’s plant. Both title and risk of loss are deemed by both the Company and its customers to have passed to the customers at the time the goods leave the Company’s plant. Shipments are only made after confirmation that a valid purchase order has been received and that the future collection of the sale amount is reasonably assured. All sales of the Company’s products are deemed final, and there is no obligation on the part of the Company to repurchase or allow the return of the goods unless they are defective. The Company does not make sales on consignment, and the collection of the proceeds of the sale is not contingent upon the customer being able to sell the goods to a third party.
	Any allowance for returns is taken as a reduction of sales within the same period the revenue is recognized. Such allowances are based on historical experience. The Company has not experienced significant fluctuations between estimated allowances and actual activity.
	From time to time during 2014 the Company offered discounts and/or rebates to some of its customers in order to retain or increase sales to those customers. In 2014 those sales discounts totaled $119,965, compared with $11,000 in 2013. Of the $119,965 in sales discounts in 2014, $23,965 had been paid, and $96,000 accrued, as of December 31, 2014. The $96,000 of accrued sales discounts consisted of rebates given to one of the Company’s largest customers in order to retain and increase its business with that customer.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents
	For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at inception. The Company deposits cash and cash equivalents with high credit quality financial institutions and believes that any amounts in excess of insurance limitations to be at minimal risk. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation up to a maximum of $250,000.
Stockholders' Equity, Policy [Policy Text Block]	Dividends
	On May 14, 2014, the Company’s Board of Directors declared a semi-annual cash dividend of $0.48 per share, which was paid on June 13, 2014 to all stockholders of record as of May 30, 2014. On November 20, 2014, the Company’s Board of Directors declared a semi-annual cash dividend of $0.32 per share, which was paid on December 22, 2014 to all stockholders of record as of December 8, 2014. Total dividends declared and paid in 2014 were $3,677,151.
	On May 15, 2013, the Company’s Board of Directors declared a semi-annual cash dividend of $0.47 per share, which was paid on June 14, 2013 to all stockholders of record as of May 30, 2013. On November 22, 2013, the Company’s Board of Directors declared a semi-annual cash dividend of $0.50 per share, which was paid on December 20, 2013 to all stockholders of record as of December 6, 2013. Total dividends declared and paid in 2013 were $4,458,544.
Supplemental Disclosures of Non-Cash Investing and Financing Activities [Policy Text Block]	Supplemental Disclosures of Non-cash Investing and Financing Activities
	Cash payments for income taxes were $1,867,089 and $2,605,474 for the years ended December 31, 2014 and 2013, respectively.
Marketable Securities, Policy [Policy Text Block]	Marketable Securities
	Marketable securities include investments in equity and fixed income mutual funds, and government securities, all of which have a high degree of liquidity, are classified as "Available for Sale" securities, and are reported at their fair values. Unrealized gains and losses on "Available for Sale" securities are reported as accumulated other comprehensive income (loss) in stockholders' equity, net of the related tax effects. Investment income is recognized when earned. Realized gains and losses on sales of investments and declines in value judged to be other than temporary, if any, are reported in other income with cost being determined on a specific identification basis. Fair values are based on quoted market prices. The Company evaluates its investments periodically for possible impairment and reviews factors such as the length of time and extent to which fair value has been below cost basis and the Company’s ability and intent to hold the investment for a period of time which may be sufficient for anticipated recovery in market value.
Inventory, Policy [Policy Text Block]	Inventories
	Inventories are valued at the lower of cost or current market value. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Inventory costs include material, labor and factory overhead.
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant and Equipment
	Property, plant and equipment are carried at cost, less accumulated depreciation. Major replacements and betterments are capitalized, while routine maintenance and repairs are expensed as incurred. Assets are depreciated under both accelerated and straight-line methods. Depreciation charged to income as a result of using accelerated methods was not materially different than that which would result from using the straight-line method for all periods presented. Certain factory equipment and fixtures are constructed by the Company using purchased materials and in-house labor. Such assets are capitalized and depreciated on a basis consistent with the Company's purchased fixed assets.
	Estimated useful lives are as follows:
	Factory equipment and fixtures (years)	5	-	7
	Building  (years)		40
	Building improvements		Lesser of useful
			life or 20 years
	Waste disposal system  (years)		7
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets
	Long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.  No impairments were necessary at December 31, 2014 and 2013.
Other Assets [Policy Text Block]	Other Assets
	Other assets at December 31, 2014 consisted of $60,042 expended in connection with the development of a new dosage form and manufacturing process for RENACIDIN, and $8,000 in costs incurred in re-registering the Company’s LUBRAJEL trademark. The Company will determine the appropriate amortization rate for these assets at such time as they are put into service.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments
	Management of the Company believes that the fair value of financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximates their carrying value due to their short payment terms and liquid nature.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk
	Accounts receivable potentially exposes the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history to determine how much credit to allow or whether any credit should be given at all.  It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable.  As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its accounts receivable credit risk has been reduced.
	For the year ended December 31, 2014, two of the Company’s distributors and marketing partners accounted for 64.7% of the Company’s revenues during the year, and 56.3% of its outstanding accounts receivable at year end. For the year ended December 31, 2013, two of the Company’s distributors and marketing partners, one the same as in 2014, and the other different, accounted for a total of 69% of the Company’s revenues during the year, and 72% of its outstanding accounts receivable at year end.
Vendor Concentration [Policy Text Block]	Vendor Concentration
	The principal raw materials used by the Company consist of common industrial organic and inorganic chemicals. Most of these materials are available in ample supply from numerous sources. The Company has five major raw material vendors that collectively accounted for approximately 84% and 67% of the raw material purchases by the Company in 2014 and 2013, respectively.
Income Tax, Policy [Policy Text Block]	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to the temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.
	Uncertain tax positions are accounted for utilizing a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As of December 31, 2014 and 2013, the Company did not have any unrecognized income tax benefits.  It is the Company’s policy to recognize interest and penalties related to taxes as interest expense as incurred.  During the years ended December 31, 2014 and 2013 the Company did not record any interest or penalties. The Company’s tax returns are subject to examination by the United States Internal Revenue Service and by the State of New York for years 2010 through 2013. In March 2014 the New York State Department of Taxation and Finance (“DTF”) commenced a routine examination of the Company’s income tax returns for years 2010 through 2012. The DTF has completed its examination and has accepted the tax returns as filed.
Research, Development, and Computer Software, Policy [Policy Text Block]	Research and Development
	The Company's research and development expenses, included in operating expenses, are recorded in the year incurred. Research and development expenses were approximately $730,000 and $717,000 for the years ended December 31, 2014 and 2013, respectively.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Costs
	Shipping and handling costs are classified in operating expenses in the accompanying statements of income. Shipping and handling costs were approximately $86,000 and $45,000 for the years ended December 31, 2014 and 2013, respectively.
Advertising Costs, Policy [Policy Text Block]	Advertising Costs
	Advertising costs are expensed as incurred. During 2014 and 2013 the Company incurred $20,000 and $16,000, respectively, in advertising costs.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation
	In 2004, the Company approved a stock option plan ("2004 Stock Option Plan") authorizing the granting of stock options to Company employees and Directors. No options were ever issued under this plan, and it expired in March 2014.
Earnings Per Share, Policy [Policy Text Block]	Earnings Per Share Information
	Basic earnings per share are computed by dividing net income by the weighted average number of common shares outstanding during the year. Diluted earnings per share include the dilutive effect of outstanding stock options.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
	In preparing financial statements in conformity with U.S. generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for bad debts, possible impairment of marketable securities, reserve for inventory obsolescence, and the allocation of overhead.
New Accounting Pronouncements, Policy [Policy Text Block]	New Accounting Standards
	In December of 2013, FASB issued ASU 2013-11, “Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” This amendment requires that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with exceptions.  This amendment only applies to entities that have an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. This update became effective for interim and annual reporting periods beginning after December 15, 2013. The update does not have a material impact on the Company’s results of operation.
	In May 2014, FASB issued ASU 2014-09, “Revenue from Contracts with Customers.” This standard applies to any entity that uses the guidance of GAAP for entering into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. It requires that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration the entity expects to receive for the exchange of goods or services. This amendment is effective for interim and annual reporting periods beginning after December 15, 2016. The Company is still evaluating the potential impact on the Company’s results of operations.
	In June 2014, FASB issued ASU 2014-11, “Transfers and Servicing: Repurchase-to-Maturity Transactions, Repurchase Financings, and Disclosures.” This standard aligns the accounting for repurchases-to-maturity transactions and repurchase agreements executed as a repurchase financing with accounting for other typical repurchase agreements. These types of transactions will now be accounted for as secured borrowings. It eliminates sales accounting for repurchase-to-maturity and supersedes guidance for accounting transactions involving transfers of financial assets with contemporaneous repurchase financing agreements that leads to off-balance accounting. This update becomes effective for interim and annual reporting periods beginning after December 15, 2014 and is not expected to have a material impact on the Company’s results of operations.
	In August 2014, FASB issued ASU 2014-15, “Presentation of Financial Statements-Going Concern.  Disclosure of Uncertainties about Entity’s Ability to Continue as a Going Concern.” Currently, GAAP lacks guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern. This amendment now provides guidance by providing a definition of substantial doubt, requires evaluation by management every reporting period for going concern issues, provides principles for considering any mitigating effects implemented by management, and the disclosures required for the assessment period of one year after issuance of the financial statements. This update becomes effective for interim and annual reporting periods beginning after December 15, 2016 with early application being permitted. The update will be adopted for reporting periods starting January 2015, and is not expected to have a material impact on the Company’s results of operations.

Note_A_Nature_of_Business_and_1

Note A - Nature of Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Property, Plant, And Equipment Useful Lives [Table Text Block]	Factory equipment and fixtures (years)	5	-	7
	Building  (years)		40
	Building improvements		Lesser of useful
			life or 20 years
	Waste disposal system  (years)		7

Note_B_Marketable_Securities_T

Note B - Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2014
Investments, Debt and Equity Securities [Abstract]
Schedule of Available-for-sale Securities Reconciliation [Table Text Block]	31-Dec-14	Cost		Fair Value		Unrealized
						Gain/(Loss)
	Available for sale:
	Fixed income mutual funds	$	8,373,674	$	8,575,285	$	201,611
	Equity and other mutual funds		622,086		814,216		192,130
		$	8,995,760	$	9,389,501	$	393,741
	31-Dec-13
	Available for sale:
	Corporate bonds (maturing within 1 year)	$	203,920	$	200,053	$	(3,867	)
	Fixed income mutual funds		7,325,930		7,425,687		99,757
	Equity and other mutual funds		1,131,147		1,237,465		106,318
		$	8,660,997	$	8,863,205	$	202,208

Note_C_Inventories_Tables

Note C - Inventories (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]		December 31,
		2014		2013
	Raw materials and work-in-process	$	395,092	$	488,757
	Finished products		842,062		1,121,990
		$	1,237,154	$	1,610,747

Note_D_Income_Taxes_Tables

Note D - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]		Years ended December 31,
		2014			2013
	Current
	Federal	$	1,714,387		$	2,721,068
	State		(9,579	)		19,646
			1,704,808			2,740,714
	Deferred
	Federal		(4,003	)		(11,810	)
	State		3,749			(351	)
			(254	)		(12,161	)
	Total provision for income taxes	$	1,704,554		$	2,728,553
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]		Years ended December 31,
		2014						2013
		($)			Tax rate			($)			Tax rate
	Income taxes at statutory federal income tax rate of 34%	$	1,957,000			34	%	$	2,935,000			34	%
	State income taxes, net of Federal benefit		(4,000	)		(0.1	)		13,000			0.2
	Domestic Production Activities tax benefit		(168,000	)		(2.9	)		(180,000	)		(2.1	)
	Nondeductible expenses		1,000			---			1,000			---
	Prior year over-accrual		(56,000	)		(1.0	)		(19,000	)		(0.2	)
	R&D credits		(25,000	)		(0.4	)		(20,000	)		(0.2	)
	Other, misc.		---			---			(1,000	)		---
	Actual income tax expense	$	1,705,000			29.6	%	$	2,729,000			31.7	%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]		Years ended December 31,
		2014			2013
	Deferred tax assets
	Current
	Accounts receivable	$	10,164		$	6,089
	Inventories		14,037			16,862
	Accrued expenses		199,238			206,500
			223,439			229,451
	Deferred tax liabilities
	Non-current
	Depreciation		(93,236	)		(99,502	)
	Unrealized gain on marketable securities		(133,872	)		(70,085	)
			(227,108	)		(169,587	)
	Net deferred tax (liability) asset	$	(3,669	)	$	59,864

Note_F_Geographic_and_Other_In1

Note F - Geographic and Other Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]		Years ended December 31,
		2014			2013
	Personal Care	$	9,421,041		$	11,459,482
	Medical		2,494,205			3,028,659
	Pharmaceutical		1,686,563			916,927
	Industrial and other		169,486			164,014
			13,771,295			15,569,082
	Less: Discounts and allowances		(321,616	)		(152,189	)
		$	13,449,679		$	15,416,893
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]		Years ended December 31,
		2014						2013
		Revenues			Long-Lived			Revenues		Long-Lived
					Assets					Assets
	United States	$	4,723,779		$	1,207,903		$	4,580,429	$	1,334,501
	China		3,500,955			---			3,519,450		---
	Canada		2,436,596			---			3,390,619		---
	United Kingdom		703,142			---			846,730		---
	India		615,890						431,015
	France		582,478			---			856,285		---
	Other countries		886,839			---			1,792,365		---
		$	13,449,679		$	1,207,903		$	15,416,893	$	1,334,501
Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]		Years ended December 31,
		2014			2013
	Customer A	$	7,929,208		$	9,712,382
	Customer B		582,478			856,285
	Customer C		615,890			431,015
	All other customers		4,322,103			4,417,211
		$	13,449,679		$	15,416,893

Note_G_Comprehensive_Income_Ta

Note G - Comprehensive Income (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in Accumulated Other	31-Dec-14			31-Dec-13
	Comprehensive Income
	Beginning balance - net of tax	$	132,123		$	178,979
	Unrealized gain/(loss) on marketable securities before reclassifications - net of tax		152,873			(65,531	)
	Realized (loss)/gain on sale of securities reclassified from accumulated other comprehensive income		(25,127	)		18,675
	Ending balance - net of tax	$	259,869		$	132,123

Note_I_Accrued_Expenses_Tables

Note I - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2014
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Schedule of Accrued Liabilities [Table Text Block]		2014		2013
	Bonuses	$	225,000	$	250,000
	Distribution fees		203,483		196,558
	Payroll and related expenses		127,585		104,394
	Annual report expenses		61,000		66,000
	Audit fee		82,000		73,269
	Sales rebates		96,000		---
	Other		38,791		37,794
		$	833,859	$	728,015

Note_A_Nature_of_Business_and_2

Note A - Nature of Business and Summary of Significant Accounting Policies (Details) (USD $)	0 Months Ended			12 Months Ended		0 Months Ended
	Dec. 22, 2014	Jun. 13, 2014	Jun. 14, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 20, 2013
Note A - Nature of Business and Summary of Significant Accounting Policies (Details) [Line Items]
Number of Major Product Lines				2
Sales Discounts, Goods				$119,965	$11,000
Sales Discounts Paid				23,965
Accrued Marketing Costs, Current				96,000
Cash, FDIC Insured Amount				250,000
Common Stock, Dividends, Per Share, Cash Paid (in Dollars per share)	$0.32	$0.48	$0.47
Payments of Ordinary Dividends, Common Stock				3,677,151	4,458,544
Income Taxes Paid				1,867,089	2,605,474
Impairment of Long-Lived Assets Held-for-use				0	0
Other Assets, Noncurrent				68,042	9,147
Number of Customers				2	2
Number of Vendors				5	5
Unrecognized Tax Benefits				0	0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued				0	0
Research and Development Expense				730,000	717,000
Shipping, Handling and Transportation Costs				86,000	45,000
Advertising Expense				20,000	16,000
Special Dividend [Member]
Note A - Nature of Business and Summary of Significant Accounting Policies (Details) [Line Items]
Common Stock, Dividends, Per Share, Cash Paid (in Dollars per share)						$0.50
LUBRAJELB. And RENACIDIN IRRIGATIONB. [Member] | Sales Revenue, Net [Member] | Product Concentration Risk [Member]
Note A - Nature of Business and Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage				94.60%	94.40%
LUBRAJEL [Member] | Sales Revenue, Net [Member] | Product Concentration Risk [Member]
Note A - Nature of Business and Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage				85.90%	91.40%
RENACIDIN [Member] | Sales Revenue, Net [Member] | Product Concentration Risk [Member]
Note A - Nature of Business and Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage				8.80%	2.90%
Capitalized Product Development Cost for RENACIDIN [Member]
Note A - Nature of Business and Summary of Significant Accounting Policies (Details) [Line Items]
Other Assets, Noncurrent				60,042
Capitalized Trademark Registration Cost for LUBRAJEL [Member]
Note A - Nature of Business and Summary of Significant Accounting Policies (Details) [Line Items]
Other Assets, Noncurrent				8,000
Sales Revenue, Net [Member] | Product Concentration Risk [Member]
Note A - Nature of Business and Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage				32.00%	36.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Note A - Nature of Business and Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage				64.70%	69.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Note A - Nature of Business and Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage				56.30%	72.00%
Cost of Goods, Product Line [Member] | Supplier Concentration Risk [Member]
Note A - Nature of Business and Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage				84.00%	67.00%
Rebates [Member]
Note A - Nature of Business and Summary of Significant Accounting Policies (Details) [Line Items]
Accrued Marketing Costs, Current				$96,000

Note_A_Nature_of_Business_and_3

Note A - Nature of Business and Summary of Significant Accounting Policies (Details) - Property, Plant, and Equipment Useful Lives	12 Months Ended
	Dec. 31, 2014
Factory Equipment and Fixtures [Member] | Minimum [Member]
Note A - Nature of Business and Summary of Significant Accounting Policies (Details) - Property, Plant, and Equipment Useful Lives [Line Items]
Property, plant and equipment useful lives	5 years
Factory Equipment and Fixtures [Member] | Maximum [Member]
Note A - Nature of Business and Summary of Significant Accounting Policies (Details) - Property, Plant, and Equipment Useful Lives [Line Items]
Property, plant and equipment useful lives	7 years
Building [Member]
Note A - Nature of Business and Summary of Significant Accounting Policies (Details) - Property, Plant, and Equipment Useful Lives [Line Items]
Property, plant and equipment useful lives	40 years
Building Improvements [Member] | Maximum [Member]
Note A - Nature of Business and Summary of Significant Accounting Policies (Details) - Property, Plant, and Equipment Useful Lives [Line Items]
Property, plant and equipment useful lives	20 years
Waste Disposal System [Member]
Note A - Nature of Business and Summary of Significant Accounting Policies (Details) - Property, Plant, and Equipment Useful Lives [Line Items]
Property, plant and equipment useful lives	7 years

Note_B_Marketable_Securities_D

Note B - Marketable Securities (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Investments, Debt and Equity Securities [Abstract]
Proceeds from Sale and Maturity of Marketable Securities	$3,077,588	$4,139,018
Marketable Securities, Realized Gain (Loss)	($25,127)	$18,675

Note_B_Marketable_Securities_D1

Note B - Marketable Securities (Details) - Available-For-Sale Securities (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Available for sale:
Cost	$8,995,760	$8,660,997
Fair Value	9,389,501	8,863,205
Unrealized Gain/(Loss)	393,741	202,208
Fixed Income Mutual Funds [Member]
Available for sale:
Cost	8,373,674	7,325,930
Fair Value	8,575,285	7,425,687
Unrealized Gain/(Loss)	201,611	99,757
Equity And Other Mutual Funds [Member]
Available for sale:
Cost	622,086	1,131,147
Fair Value	814,216	1,237,465
Unrealized Gain/(Loss)	192,130	106,318
Corporate Debt Securities [Member]
Available for sale:
Cost		203,920
Fair Value		200,053
Unrealized Gain/(Loss)		($3,867)

Note_C_Inventories_Details

Note C - Inventories (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]
Inventory Valuation Reserves	$20,000	$20,000

Note_C_Inventories_Details_Inv

Note C - Inventories (Details) - Inventories (USD $)	Dec. 31, 2014	Dec. 31, 2013
Inventories [Abstract]
Raw materials and work-in-process	$395,092	$488,757
Finished products	842,062	1,121,990
	$1,237,154	$1,610,747

Note_D_Income_Taxes_Details

Note D - Income Taxes (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Percentage of Net Income from Domestic Production Activities	9.00%	9.00%

Note_D_Income_Taxes_Details_Pr

Note D - Income Taxes (Details) - Provision for Income Taxes (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Current
Federal	$1,714,387	$2,721,068
State	-9,579	19,646
	1,704,808	2,740,714
Deferred
Federal	-4,003	-11,810
State	3,749	-351
	-254	-12,161
Total provision for income taxes	$1,704,554	$2,728,553

Note_D_Income_Taxes_Details_Re

Note D - Income Taxes (Details) - Reconciliation of the Effective Income Tax Rate (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Reconciliation of the Effective Income Tax Rate [Abstract]
Income taxes at statutory federal income tax rate of 34%	$1,957,000	$2,935,000
Income taxes at statutory federal income tax rate of 34%	34.00%	34.00%
State income taxes, net of Federal benefit	-4,000	13,000
State income taxes, net of Federal benefit	-0.10%	0.20%
Domestic Production Activities tax benefit	-168,000	-180,000
Domestic Production Activities tax benefit	-2.90%	-2.10%
Nondeductible expenses	1,000	1,000
Prior year over-accrual	-56,000	-19,000
Prior year over-accrual	-1.00%	-0.20%
R&D credits	-25,000	-20,000
R&D credits	-0.40%	-0.20%
Other, misc.		-1,000
Actual income tax expense	$1,705,000	$2,729,000
Actual income tax expense	29.60%	31.70%

Note_D_Income_Taxes_Details_De

Note D - Income Taxes (Details) - Deferred Tax Assets and Liabilities (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current
Accounts receivable	$10,164	$6,089
Inventories	14,037	16,862
Accrued expenses	199,238	206,500
	223,439	229,451
Non-current
Depreciation	-93,236	-99,502
Unrealized gain on marketable securities	-133,872	-70,085
	-227,108	-169,587
Net deferred tax (liability) asset	($3,669)	$59,864

Note_E_Benefit_Plans_Details

Note E - Benefit Plans (Details) (DC Plan [Member], USD $)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Note E - Benefit Plans (Details) [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay		4.00%	4.00%
Defined Contribution Plan, Discretionary Contribution Vesting Period		1 year	1 year
Defined Contribution Plan, Employer Discretionary Contribution Amount		103,000	$101,000
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount		17,500	17,500
Defined Contribution Plan Employer Discretionary Contribution Amount Per Year Authorized		175,000	175,000
Defined Contribution Plan, Discretionary Contributions Fully Vested Term, Years		6
Scenario, Forecast [Member] | Additional Deferred Investment Employees Over 50 [Member]
Note E - Benefit Plans (Details) [Line Items]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount	6,000
Scenario, Forecast [Member]
Note E - Benefit Plans (Details) [Line Items]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount	18,000
Discretionary Contribution Vesting at Two Years [Member]
Note E - Benefit Plans (Details) [Line Items]
Defined Contribution Plan, Discretionary Contribution Vesting Period		2 years
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage		20.00%
Discretionary Contributions Vesting Each Additional Year [Member]
Note E - Benefit Plans (Details) [Line Items]
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage		20.00%
Additional Deferred Investment Employees Over 50 [Member]
Note E - Benefit Plans (Details) [Line Items]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount		5,500	$5,500

Note_F_Geographic_and_Other_In2

Note F - Geographic and Other Information (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Note F - Geographic and Other Information (Details) [Line Items]
Number of Operating Segments	1	1
Number of Customers	2	2
Sales Revenue, Net [Member] | Product Concentration Risk [Member]
Note F - Geographic and Other Information (Details) [Line Items]
Concentration Risk, Percentage	32.00%	36.00%

Note_F_Geographic_and_Other_In3

Note F - Geographic and Other Information (Details) - Net Sales (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Sales	$13,771,295	$15,569,082
Less: Discounts and allowances	-321,616	-152,189
	13,449,679	15,416,893
Personal Care [Member]
Segment Reporting Information [Line Items]
Sales	9,421,041	11,459,482
Medical [Member]
Segment Reporting Information [Line Items]
Sales	2,494,205	3,028,659
Pharmaceuticals [Member]
Segment Reporting Information [Line Items]
Sales	1,686,563	916,927
Industrial and Other [Member]
Segment Reporting Information [Line Items]
Sales	$169,486	$164,014

Note_F_Geographic_and_Other_In4

Note F - Geographic and Other Information (Details) - Geographic Information (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$13,449,679	$15,416,893
Long-Lived Assets	1,207,903	1,334,501
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	4,723,779	4,580,429
Long-Lived Assets	1,207,903	1,334,501
CHINA
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	3,500,955	3,519,450
CANADA
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	2,436,596	3,390,619
UNITED KINGDOM
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	703,142	846,730
INDIA
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	615,890	431,015
FRANCE
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	582,478	856,285
Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$886,839	$1,792,365

Note_F_Geographic_and_Other_In5

Note F - Geographic and Other Information (Details) - Sales to Major Customers (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting, Other Significant Reconciling Item [Line Items]
Sales	$13,449,679	$15,416,893
Customer A [Member]
Segment Reporting, Other Significant Reconciling Item [Line Items]
Sales	7,929,208	9,712,382
Customer B [Member]
Segment Reporting, Other Significant Reconciling Item [Line Items]
Sales	582,478	856,285
Customer C [Member]
Segment Reporting, Other Significant Reconciling Item [Line Items]
Sales	615,890	431,015
All Other Customers [Member]
Segment Reporting, Other Significant Reconciling Item [Line Items]
Sales	$4,322,103	$4,417,211

Note_G_Comprehensive_Income_De

Note G - Comprehensive Income (Details) - Accumulated Other Comprehensive Income (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]
Ending balance - net of tax	$259,869	$132,123
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance - net of tax	132,123	178,979
Unrealized gain/(loss) on marketable securities before reclassifications - net of tax	152,873	-65,531
Realized (loss)/gain on sale of securities reclassified from accumulated other comprehensive income	-25,127	18,675
Ending balance - net of tax	$259,869	$132,123

Note_H_Income_From_Damage_Sett1

Note H - Income From Damage Settlement (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2013
Note H - Income From Damage Settlement (Details) [Line Items]
Other Receivables, Net, Current		$48,805
Damage Settlement [Member]
Note H - Income From Damage Settlement (Details) [Line Items]
Other Receivables, Net, Current			518,050
Proceeds from Legal Settlements	24,403	1,070,561
Damage Settlement Monthly [Member]
Note H - Income From Damage Settlement (Details) [Line Items]
Other Receivables, Net, Current				97,610
Damage Settlement Two Months [Member]
Note H - Income From Damage Settlement (Details) [Line Items]
Other Receivables, Net, Current		48,805
Damage Settlement Third Month [Member]
Note H - Income From Damage Settlement (Details) [Line Items]
Other Receivables, Net, Current		$24,403

Note_I_Accrued_Expenses_Detail

Note I - Accrued Expenses (Details) - Accrued Expenses (USD $)	Dec. 31, 2014	Dec. 31, 2013
Note I - Accrued Expenses (Details) - Accrued Expenses [Line Items]
Bonuses	$225,000	$250,000
Distribution fees	203,483	196,558
Payroll and related expenses	127,585	104,394
Sales rebates	96,000
Other	38,791	37,794
	833,859	728,015
Accrued Annual Report [Member]
Note I - Accrued Expenses (Details) - Accrued Expenses [Line Items]
Accrued professional fees	61,000	66,000
Accrued Audit Fee [Member]
Note I - Accrued Expenses (Details) - Accrued Expenses [Line Items]
Accrued professional fees	$82,000	$73,269

Note_J_Related_Party_Transacti1

Note J - Related Party Transactions (Details) (Director [Member], Accounting and Tax Services [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Director [Member] | Accounting and Tax Services [Member]
Note J - Related Party Transactions (Details) [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party	$17,000	$14,000